Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for PURE Bioscience (PURE : OTCBB)
 
 • Company Description   
PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including methicillin-resistant Staphylococcus aureus (MRSA), or staph infection. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of `green` products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it.

Number of Employees: 11

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.19 Daily Weekly Monthly
20 Day Moving Average: 22,839 shares
Shares Outstanding: 88.02 (millions)
Market Capitalization: $16.99 (millions)
Beta: -0.02
52 Week High: $0.55
52 Week Low: $0.16
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 3.49% 16.54%
12 Week -3.50% 6.08%
Year To Date 1.21% 21.80%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
9669 HERMOSA AVENUE
-
RANCHO CUCAMONGA,CA 91730
USA
ph: 619-596-8600
fax: 619-596-8790
melliott@purebio.com http://www.purebio.com
 
 • General Corporate Information   
Officers
Tom Y. Lee - Chief Executive Officer
Ivan Chen - Chairman of the Board
Mark S. Elliott - Vice President; Finance Principal Financial and Ac
Tom Myers - Director
Kristin Taylor - Director

Peer Information
PURE Bioscience (BJCT)
PURE Bioscience (CADMQ)
PURE Bioscience (APNO)
PURE Bioscience (UPDC)
PURE Bioscience (IMTIQ)
PURE Bioscience (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 74621T209
SIC: 2890
Fiscal Year
Fiscal Year End: July
Last Reported Quarter: 01/01/22
Next Expected EPS Date: 06/21/22
Share - Related Items
Shares Outstanding: 88.02
Most Recent Split Date: 8.00 (0.13:1)
Beta: -0.02
Market Capitalization: $16.99 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 06/21/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 7.69
Price/Cash Flow: -
Price / Sales: 7.27
EPS Growth
vs. Year Ago Period: 0.00%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -54.59%
vs. Previous Quarter: -16.97%
ROE
04/30/22 - -
01/31/22 - -107.81
10/31/21 - -81.11
ROA
04/30/22 - -
01/31/22 - -84.71
10/31/21 - -65.26
Current Ratio
04/30/22 - -
01/31/22 - 2.98
10/31/21 - 2.96
Quick Ratio
04/30/22 - -
01/31/22 - 2.47
10/31/21 - 2.59
Operating Margin
04/30/22 - -
01/31/22 - -140.39
10/31/21 - -103.45
Net Margin
04/30/22 - -
01/31/22 - -130.17
10/31/21 - -103.45
Pre-Tax Margin
04/30/22 - -
01/31/22 - -130.17
10/31/21 - -103.45
Book Value
04/30/22 - -
01/31/22 - 0.03
10/31/21 - 0.03
Inventory Turnover
04/30/22 - -
01/31/22 - 3.18
10/31/21 - 3.02
Debt-to-Equity
04/30/22 - -
01/31/22 - 0.00
10/31/21 - 0.00
Debt-to-Capital
04/30/22 - -
01/31/22 - 0.00
10/31/21 - 0.00
 

Powered by Zacks Investment Research ©